Technical Analysis for CGTX - Cognition Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.01 | 2.55% | 0.05 |
Earnings due: Jun 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 2.55% | |
| Bollinger Band Squeeze | Range Contraction | 2.55% | |
| NR7 | Range Contraction | 2.55% | |
| Narrow Range Bar | Range Contraction | 2.55% | |
| Fell Below 20 DMA | Bearish | 3.61% | |
| 50 DMA Support | Bullish | 3.61% | |
| Bollinger Band Squeeze | Range Contraction | 3.61% | |
| 20 DMA Support | Bullish | 3.08% | |
| 50 DMA Support | Bullish | 3.08% | |
| Bollinger Band Squeeze | Range Contraction | 3.08% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 1 hour ago |
| Up 3% | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
| Rose Above Upper Bollinger Band | about 1 hour ago |
| Up 2% | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/07/2024
Cognition Therapeutics, Inc. Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Biology Alzheimer's Disease Parkinson's Disease Disorders Dementia Psychiatric Diagnosis Geriatrics Aging Associated Diseases Lewy Body Dementia Cognitive Disorders Dry Age Related Macular Degeneration Early Stage Alzheimer's Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.44 |
| 52 Week Low | 0.9001 |
| Average Volume | 149,470 |
| 200-Day Moving Average | 1.69 |
| 50-Day Moving Average | 1.92 |
| 20-Day Moving Average | 1.95 |
| 10-Day Moving Average | 1.95 |
| Average True Range | 0.11 |
| RSI (14) | 51.22 |
| ADX | 22.94 |
| +DI | 17.97 |
| -DI | 10.17 |
| Chandelier Exit (Long, 3 ATRs) | 1.77 |
| Chandelier Exit (Short, 3 ATRs) | 2.12 |
| Upper Bollinger Bands | 2.02 |
| Lower Bollinger Band | 1.88 |
| Percent B (%b) | 0.58 |
| BandWidth | 7.06 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.04 | ||||
| Resistance 3 (R3) | 2.03 | 2.01 | 2.02 | ||
| Resistance 2 (R2) | 2.01 | 1.99 | 2.01 | 2.02 | |
| Resistance 1 (R1) | 1.98 | 1.98 | 2.00 | 1.99 | 2.01 |
| Pivot Point | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 |
| Support 1 (S1) | 1.93 | 1.94 | 1.95 | 1.94 | 1.91 |
| Support 2 (S2) | 1.91 | 1.93 | 1.91 | 1.90 | |
| Support 3 (S3) | 1.88 | 1.91 | 1.90 | ||
| Support 4 (S4) | 1.89 |
